Dataset Information


Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.

ABSTRACT: BACKGROUND:We investigated the role of prostaglandin receptors (e.g. prostaglandin E2 receptor 2 (EP2), EP4) and the efficacy of celecoxib in urothelial tumourigenesis and cancer progression. METHODS:We performed immunohistochemistry in bladder cancer (BC) tissue microarrays, in vitro transformation assay in a normal urothelial SVHUC line, and western blot/reverse transcription-polymerase chain reaction/cell growth assays in BC lines. RESULTS:EP2/EP4 expression was elevated in BCs compared with non-neoplastic urothelial tissues and in BCs from those who were resistant to cisplatin-based neoadjuvant chemotherapy. Strong positivity of EP2/EP4 in non-muscle-invasive tumours or positivity of EP2/EP4 in muscle-invasive tumours strongly correlated with disease progression or disease-specific mortality, respectively. In SVHUC cells, exposure to a chemical carcinogen 3-methylcholanthrene considerably increased and decreased the expression of EP2/EP4 and phosphatase and tensin homologue (PTEN), respectively. Treatment with selective EP2/EP4 antagonist or celecoxib also resulted in prevention in 3-methylcholanthrene-induced neoplastic transformation of SVHUC cells. In BC lines, EP2/EP4 antagonists and celecoxib effectively inhibited cell viability and migration, as well as augmented PTEN expression. Furthermore, these drugs enhanced the cytotoxic activity of cisplatin in BC cells. EP2/EP4 and PTEN were also elevated and reduced, respectively, in cisplatin-resistant BC sublines. CONCLUSIONS:EP2/EP4 activation correlates with induction of urothelial cancer initiation and outgrowth, as well as chemoresistance, presumably via downregulating PTEN expression.

SUBMITTER: Kashiwagi E 

PROVIDER: S-EPMC5785746 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC4672642 | BioStudies
1000-01-01 | S-EPMC6280600 | BioStudies
2017-01-01 | S-EPMC5573328 | BioStudies
2015-01-01 | S-EPMC4467118 | BioStudies
2008-01-01 | S-EPMC2614698 | BioStudies
2017-01-01 | S-EPMC5234110 | BioStudies
2018-01-01 | S-EPMC5860864 | BioStudies
1000-01-01 | S-EPMC2716972 | BioStudies
2017-01-01 | S-EPMC5540704 | BioStudies
2007-01-01 | S-EPMC2266676 | BioStudies